Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.

about

Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.

Item

http://www.wikidata.org/entity/Q38393581

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Exposure-Response Relationship ...... ase 3 Randomized GIFT-I Study.

@en

type

Item

label

Exposure-Response Relationship ...... ase 3 Randomized GIFT-I Study.

@en

prefLabel

Exposure-Response Relationship ...... ase 3 Randomized GIFT-I Study.

@en

P1476

Exposure-Response Relationship ...... ase 3 Randomized GIFT-I Study.

@en

P2093

Amit Khatri

http://www.w3.org/2001/XMLSchema#string

Jiuhong Zha

http://www.w3.org/2001/XMLSchema#string

Rajeev Menon

http://www.w3.org/2001/XMLSchema#string

Rebecca Redman

http://www.w3.org/2001/XMLSchema#string

Sathej Gopalakrishnan

http://www.w3.org/2001/XMLSchema#string

Sven Mensing

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

A simulation study of the number of events per variable in logistic regression analysis.

Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Changing trends in hepatitis C infection over the past 50 years in Japan.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.

Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).

P2888

s12325-016-0320-y

P304

670-683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-016-0320-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008473282

http://www.w3.org/2001/XMLSchema#string

P698

27084721

http://www.w3.org/2001/XMLSchema#string

P921

ombitasvir